Skip to Content

Other Learning Opportunities for Stay-at-home Scientists Outside the NIH

SACNAS Upcoming Webinars: Insights to Success Icon NEW

Inside the Coronavirus: Special Coverage from Scientific American, fantastic graphics that explain what scientists know now about SARS-CoV-2 now and will be updated as we learn more Icon NEW

ABRCMS (The Annual Biomedical Research Conference for Minority Students) has created ABRCMS Online Icon NEW

Supporting People with Addiction During COVID-19: A webinar series from the National Academy of Medicine

When Public Health Means Business: A Harvard T.H. Chan School of Public Health / New England Journal of Medicine Virtual Symposium

The Forum: Harvard T.H. Chan School of Public Health. A series of 18 (and counting) panel discussions on the Coronavirus Pandemic

National Academy of Sciences COVID-19 Update

Earth Day Activities: August 22

Virtual Radcliffe Discussion Series: Health Inequity in the Age of COVID-19

1918 Spanish Flu historical documentary | Swine Flu Pandemic | Deadly plague of 1918

New Science Webinar from AAAS: Coronavirus: A Survival Guide

NIH COVID-19 Lecture Series Icon NEW

Visit the National Academies Press to Download FREE PDFs of Their Reports

Virtual Keystone Symposia: The Malaria Endgame (4/22)

National Academies Forum on Response to COVID-19 (4/9 and additional sessions) Recordings of all sessions are available after the live sessions.

PBS Film: “Ken Burns presents The Gene: An Intimate History”

NIGMS Virtual Learning Resources

Memorial Sloan Kettering Science Spotlight

SACNAS Insights to Success Webinars

Overcoming Discrimination
Wednesday, August 12 from 12pm to 1pm PT (NOTE Pacific Time Zone)

In this webinar, two professionals will share their stories navigating STEM spaces as a "minority", detailing personal experiences from microaggressions to blatant racism. Speakers will share what they learned, including practical tools for addressing microaggressions, advocating for inclusion and equity, identifying how to work with allies to make positive change, and propelling their careers forward despite these obstacles. Participants will have an opportunity to ask questions and share their own personal experiences to get advice.

Career and Family — Who Says You Have to Choose?
Tuesday, August 25 from 1pm to 2pm PT

No one says it's easy and there's no "right" way to do it, but you can have it all! In this webinar, three professionals will share their different approaches to having a family during their STEM education or career. Panelists will share their challenges and advice for balancing their professional and personal goals. Participants will have the opportunity to ask questions, share their experiences, and get advice.

Explore the SACNAS webinar library.


ABRCMS (The Annual Biomedical Research Conference for Minority Students) has created ABRCMS Online Icon NEW

ABRCMS Online is an extension of the conference that allows the biomedical sciences community to continue learning, with resources for students, trainees, faculty, and community.

Supporting People with Addiction During COVID-19: A webinar series from the National Academy of Medicine

Individuals experiencing addiction are a vulnerable population that have been significantly impacted by the COVID-19 pandemic. Physical distancing protocols have separated patients from their clinicians, made medications to treat addiction much more challenging to obtain, and shuttered many long-term recovery groups. 

A new webinar series from the NAM and the American Society of Addiction Medicine will provide insight and targeted guidance on how to ensure that these individuals are cared for and protected during this ongoing public health crisis.

Webinar 1: Helping People with Addiction Stay Connected during COVID-19. Available as a video recording.


When Public Health Means Business: A Harvard T.H. Chan School of Public Health / New England Journal of Medicine Virtual Symposium


“When Public Health Means Business” is a multi-part series that virtually convenes luminaries from the realms of finance, industry and health to map a new path forward and ensure a better, safer future for all. Jointly presented by the Harvard T.H. Chan School of Public Health and the New England Journal of Medicine, and hosted by The Forum at the Harvard T.H. Chan School of Public Health.

The four sessions are available on demand, below.

Part 1: The current COVID-19 pandemic has revealed a plain truth: We can no longer afford to operate in silos. Instead, this once-in-a-lifetime public health crisis demands a remarkable level of cooperation across sectors and disciplines. Now more than ever, public health and business need to forge ahead together to clear the runway for our economy and society to thrive.

What will it take to move forward globally? How do we battle the war against science? What will it take to succeed? How can we prepare now for the next pandemic?

In Part 2, we will build on that framework, examining how the value created by public health is equal to if not greater than the shareholder value created in business; how are businesses to function while waiting for COVID-19 vaccines and treatments; and should we consider privatizing the public health system?

 In Part 3, the series continues with a dynamic discussion between Lawrence H. Summers, President Emeritus and Charles W. Eliot University Professor at Harvard University, and Stephanie Ruhle, NBC News Business Correspondent and Host of 'MSNBC Live'. They will examine how and why the public health and business sectors must engage for the economy and society to thrive now and well after the COVID-19 pandemic. 

Part 4. Dr. Anthony Fauci, the nation’s top infectious disease specialist, answers questions from Harvard Chan faculty and other COVID-19 experts, going narrow and deep on questions about the pandemic that you won’t hear anywhere else. The session is moderated by Dr. Sanjay Gupta, Chief Medical Correspondent for CNN.

 The Forum: Harvard T.H. Chan School of Public Health. A series of 18 panel discussions (and counting) on the Coronavirus Pandemic

May 26, 2020, 12:00 pm EDT

Email your questions to or post them to Facebook @ForumHSPH or @pritheworld.

Did You Miss Some? Watch Them and More On Demand.


The Coronavirus Pandemic: Equity, Impacts and Global Fragile Communities (August 11th, noon, EDT)

#First RespondersFirst: The Path Forward (July 29)

The Coronavirus Pandemic: Unequal Risks for Communities of Color (July 21st)

The Coronavirus Pandemic: Advances in Testing, Fighting the Surge (July 14th)

The Coronavirus Pandemic: Surging Cases, A Growing Crisis (July 7th)

Food Insecurity, Inequality, and COVID-10 (June 30, 12:00 pm EDT)

The Coronavirus Pandemic: What's Next? with Caroline Buckee (June 23)

Racism and COVID-19, with David Harris, (June 18)

The Coronavirus Pandemic: Stopping the Spread of Misinformation, with K. "Vish" Vishwanath (May 26)

The Coronavirus Pandemic: Responding Now and Averting Future Crises, with Howard Koh (May 19)

The Coronavirus Pandemic: Antibody Testing and Reopening Society, with Dr. Michael Mina (May 15)

The Coronavirus Pandemic: Safely Reopening Workplaces, with Dr. Joseph Allen (May 12, 2020)

The Coronavirus Pandemic: Potential Vaccines and Treatments, with Dr. Barry Bloom (May 7, 2020)

The Coronavirus Pandemic: Mental Health, Stress and Resiliency, with Karestan Koenen (May 5, 2020)

Voices in Leadership During Crises: Stephanie Ferguson (April 30, 2020)

The Coronavirus Pandemic: Health Inequities and Vulnerable Communities, with Mary Bassett (April 28, 2020)

COVID-19: Where do we go from here?, Presented jointly by the Harvard T.H. Chan School of Public Health and the New England Journal of Medicine (April 21, 2020)

The Coronavirus Pandemic: Hospital Frontlines During the Surge, with Paul Biddinger (April 16, 2020)


National Academy of Sciences COVID-19 Update

Saturday, April 25, 2020
2:00 p.m. EDT

  •  Jeremy Farrar, Director, Wellcome Trust (confirmed)
  •  Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases (accepted, schedule permitting)
  •  George F. Gao, Director-General, Chinese Center for Disease Control & Prevention (confirmed)
  •  Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania (confirmed)
  •  Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations (confirmed)
  •  Sanjay Gupta, Chief Medical Correspondent, CNN (confirmed)



Earth Day Activities: It's the 50th Anniversary! August 22


March for Science: Flatten the Curve Forum - April 22, 2020, 8:30am - 6:00pm


To Register:

The March for Science Media Zone April 22-26, 2020 in honor of the 50th Anniversary of Earth Day. Streaming Live on

New Documentary on the Discovery Channel: The Story of Plastic

The new documentary The Story of Plastic premieres on Discovery Network channels around the world Friday, April 22nd, Earth Day!

The Story of Plastic takes a sweeping look at the global plastic pollution crisis and how it’s affecting the health of our planet and people around the world; it’s also a story of hope, featuring the heroes who are bringing meaningful solutions to life all along the plastics supply chain.

Discovery Channel Premiere

The Story of Plastic will air on Discovery Network channels in 134 countries and territories around the world over the coming weeks.

In the United States, the movie will premiere on April 22nd at 2pm Eastern and Pacific. Please check your local listings for broadcast information and visit for more information.

Virtual Radcliffe Discussion Series: Health Inequity in the Age of COVID-19

The Radcliffe Institute is launching a new Virtual Radcliffe programming platform to offer lectures and conferences that connect leading scholars and practitioners with the public and advance discourse on pressing issues. Beginning on Thursday, April 23, Radcliffe will host a series of discussions examining the grave health inequities revealed and exacerbated by COVID-19, which is disproportionately impacting vulnerable and marginalized communities. The first event in our series will examine health equity in the context of disability.

We look forward to continuing to share announcements about upcoming virtual events in our e-newsletters throughout the remainder of the semester and summer months. You can also check our website for a list of programs.

State Prisons and COVID-19 Icon NEW

Wednesday, May 6, 1 PM

How should directors of state prison systems respond to the current pandemic? Patricia Caruso and Harold Clarke will draw on their decades of experience to address the particular challenges posed by COVID-19. They will consider possible solutions, including steps to protect both the incarcerated population and staff, repurposing prison garment shops to produce protective gear for people on the front lines, and responsible early release—all with the aim of contributing to lasting public safety.

Health, Inequity, and COVID-10 Icon NEW

April 28, 2020
Recordings of prior sessions will be posted approx. 2 weeks after the events.

International experience in recent months has powerfully illustrated that the COVID-19 virus has particularly harmful and disproportionate effects on already vulnerable populations. Mary Bassett and Khalil Gibran Muhammad will discuss inequity and public health in the time of COVID-19, exploring how the virus encounters existing inequalities, replicates these inequalities, and, in many cases, amplifies them.

Ensuring Health Equity for Persons with Disabilities: The Context and Ethics of Health Rationing Protocols during COVID-19

Thursday, April 23, 4 PM
Recordings of prior sessions will be posted approx. 2 weeks after the events

As COVID-19 threatens to push hospital resources beyond capacity, states, hospitals, and advocacy organizations have formulated protocols to address potential discrimination against persons with disabilities. Highly influential statements by the Arc and the University of Pittsburgh are setting new standards for the ethical treatment of persons with disabilities. This Radcliffe webinar places these triaging policies within the context of the history of disability civil rights, culture, and bioethics and considers what is necessary to achieve equitable health outcomes for persons with disabilities during this time of crisis.

1918 Spanish Flu historical documentary | Swine Flu Pandemic | Deadly plague of 1918

Historical documentary about 1918 Swine Flu or Spanish Flu and the role of World War I in spreading the disease among troops making it into a worldwide plague of devastating proportions. The video covers where it began, how and where it spread, the symptoms, how it affected America and whether it could happen again.

New Science Webinar from AAAS: Coronavirus: A Survival Guide

Thursday, 16 April 2020, 11 a.m. Eastern, 8 a.m. Pacific, 4 p.m. UK (BST), 5 p.m. Central Europe (CEST)
Now available on demand.

  • What the coronavirus is and how it makes you sick
  • What you can do to protect yourself, and keep your friends and family safe
  • How you can build resilience to deal with this new way of life
  • What the end of this pandemic might look like 
  • Where you can get the latest information about the virus that is accurate and trustworthy.



SARS-CoV-2 T Cell Responses in Exposed and Non-Exposed Subjects

The NIH COVID-19 Scientific Interest Group is pleased to announce its next lecture, "SARS-CoV-2 T Cell Responses in Exposed and Non-Exposed Subjects," by Alessandro Sette, Ph.D., professor and member of the La Jolla Institute for Immunology, La Jolla, Calif.

This lecture will be on Wednesday, July 29, from 3:00 to 4:00 p.m. ET via  Please see viewing instructions below.  This lecture will be the last talk in the COVID-19 lecture series for two months.  We will resume in October.   

Lecture summary:

For his lecture, Dr. Sette will review data examining the nature and specificity of T cell responses to SARS-CoV-2 from convalescent and acute donors, and in non-exposed subjects.  Over the past three decades, the Sette lab has defined in chemical terms the specific structures that the immune system recognizes, and it has capitalized on this knowledge to measure and understand immune responses.  This approach uses epitopes as specific probes to define the immune signatures associated with productive/protective immunity versus deficient immunity/immunopathology.  Turning to SARS-CoV-2, Dr. Sette and his colleagues applied this approach to provide the one of the first assessments of whether the immune system can mount a substantial and lasting response, finding evidence of T cell reactivity against and pre-existing immunity to SARS-CoV-2.  Dr. Sette will highlight these and other findings in his talk.

This lecture will be videocast live and quickly archived at  To watch live, we suggest that you have Adobe Flash Player installed on your computer and that your web browser of choice can access Flash. 

If you cannot log on because of the high demand, please note that the archive will be available within two days.

Sign-language interpreters can be provided.  Individuals with disabilities who need reasonable accommodation to participate in this event should contact Karen Nemes,, or the Federal Relay, 800-877-8339.


COVID-19 Autopsy Findings: A Joint Effort Between NYU Winthrop Hospital and NCI — What Have We Learned So Far

The NIH COVID-19 Scientific Interest Group is pleased to announce its next lecture, "COVID-19 Autopsy Findings: A Joint Effort Between NYU Winthrop Hospital and NCI — What Have We Learned So Far," by Stefania Pittaluga, M.D., and David Kleiner, M.D., Ph.D., senior research physicians in the NCI-CCR Laboratory of Pathology, July 22. This lecture is now archived.

Since the outbreak of COVID-19 disease, caused by SARS-CoV-2 infection, many studies focusing on clinical course, outcome, clinical parameters, prognostic markers, treatment strategies have been published.  Although most patients experience mild symptoms, some have serious complications—including diffuse alveolar damage, hemodynamic shock, acute kidney failure, cardiac injury, and arrhythmia—that contribute to the high mortality rate.  Autopsies can offer a better understanding of the underlying pathophysiology.  Unfortunately few autopsies were performed early in the pandemic because of the potential risks.  Untreated patients who died of SARS-CoV-2 were rarely autopsied.  Most of the published autopsy studies have focused on lung disease with a few describing findings in other organs.  We will discuss our experience with the first set of patient autopsies performed at NYU Winthrop Hospital as well as some of our own experience here at the NIH.  We will review some of the key findings in major organ systems accompanied by immunohistochemical and in situ hybridization studies that examined some of the cytokines/chemokines that have been implicated in the pathogenesis of this viral infection.


Nucleic Acid Delivery Systems for RNA Therapy and Gene Editing

The NIH COVID-19 Scientific Interest Group is pleased to announce its next lecture, "Nucleic Acid Delivery Systems for RNA Therapy and Gene Editing," by Dan Anderson, Ph.D., professor of chemical engineering and of health sciences and technology at the MIT Koch Institute for Integrative Cancer Research, July 15. This lecture is now archived.

High–throughput, combinatorial approaches have revolutionized small-molecule drug discovery.  Dan Anderson will describe his work on the combinatorial development of nanoparticulate, intracellular delivery systems for RNA therapy and gene editing.  Libraries of degradable polymers and lipid-like materials have been synthesized, formulated, and screened for their ability to deliver macromolecular payloads inside of cells.  These nanoformulations facilitate in vivo delivery, enabling gene suppression with small-interfering RNA, gene expression with messenger RNA, or permanent genetic editing using the CRISPR/Cas9 system.  Formulations have been developed with in vivo efficacy and show potential therapeutic applications for a range of different diseases.  This lecture will focus on the application of these formulations toward controlling the immune system and in particular as vaccines for infectious disease.

Lessons Learned: Management and Treatment during COVID-19 Pandemic

The NIH COVID-19 Scientific Interest Group is pleased to announce its next lecture, "Lessons Learned: Management and Treatment during COVID-19 Pandemic," by Judith A. Aberg, M.D., chief of Infectious Diseases, Icahn School of Medicine at Mount Sinai, and a member of the panel developing NIH COVID-19 Treatment Guidelines, July 8. This lecture is now archived.

Dr. Aberg will briefly discuss what is new in the pathogenesis of SARS-CoV-2 and how this affected the decision-making processes on the management and treatment of SARS-CoV-2 infection during the COVID-19 pandemic in New York City. Even in the absence of data and insufficient knowledge of what may or may not work, the Mount Sinai Health System created treatment guidelines that were updated frequently based on physicians' observations and information gathered from multiple disciplines across the system. Dr. Aberg will present a few lessons learned that affected the quality-of-care of patients. The majority of her talk will focus on how clinical observations at the Mount Sinai Health System and how social media and knowledge imparted from colleagues across the globe influenced clinical decision making. Dr. Aberg will close the talk with a summary of how she and her colleagues are better prepared for the future, the knowledge they have gained, and the potential therapeutic options currently under investigation.


High Seroprevalence, Drastic Decline of Incidence and Low Infection Fatality Rate of SARS-CoV-2 Infections in Children and Adults in the Ski Resort Ischgl, Austria

The NIH COVID-19 Scientific Interest Group is pleased to announce its next lecture, "High Seroprevalence, Drastic Decline of Incidence and Low Infection Fatality Rate of SARS-CoV-2 Infections in Children and Adults in the Ski Resort Ischgl, Austria," by Dorothee von Laer, M.D., Medical University of Innsbruck, July 1. This lecture is now archived.

In early March 2020, a SARS-CoV-2 outbreak at a ski resort in Ischgl, Austria, initiated the spread of SARS-CoV-2 throughout Austria and Northern Europe. Thousands of infections can be traced back to Ischgl. In a recent study by Medical University of Innsbruck investigators, 42.4 percent of those living in Ischgl were shown to be carrying the new coronavirus antibodies, indicating they had been infected in the COVID-19 pandemic. Between April 21 and 27, a cross-sectional epidemiologic study targeting the full population of Ischgl (n= app. 1,867), of which 79 percent could be included (n=1473), was performed. For each individual, the study involved a SARS-CoV-2 PCR test for the virus, antibody testing, and a questionnaire. In addition, the SARS-CoV-2 PCR+ cases reported to the authorities were included. The seroprevalence was 42 percent and individuals under 18 showed a significantly lower seroprevalence (27 percent) than adults (45 percent). However, only 105 study participants remembered if they had a previous positive PCR result. The clinical course was generally mild and only two individuals in Ischgl had died from infection corresponding to an infection fatality rate (IFR) of 0.26 percent. In the first week of April, a public screening in Ischgl had found 19 percent of the population to be PCR+. However, only 8 (0.5 percent) individuals were newly diagnosed to be infected with SARS-CoV-2 during the study conducted 2-3 weeks later.  Ischgl was hit early and hard by SARS-CoV-2, which led to a high local seroprevalence of 42 percent, that was lower in individuals below the age of 18 than in adults with a low IFR. As nonpharmaceutical interventions (e.g. social distancing, mask wearing) had already reduced virus spread, mathematical models conclude that the high seroprevalence significantly contributed to the drastic decline of new infections during April.


Covid-19: A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing

The NIH COVID-19 Scientific Interest Group is pleased to announce its next lecture, "A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing," by Nevan Krogan, Ph.D., University of California, San Francisco, June 24. This lecture is now archived.

Efforts to develop antiviral drugs versus COVID-19 or vaccines for its prevention have been hampered by limited knowledge of the molecular details of SARS-CoV-2, the virus that causes COVID-19. This webinar will describe Nevan Krogan's efforts to address this challenge. He and his lab expressed 26 of the 29 SARS-CoV-2 proteins in human cells and are using affinity–purification mass spectrometry to identify the human proteins physically associated with each. Among 332 high–confidence SARS-CoV-2-human protein–protein interactions, Krogan's lab has identified 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Within a subset of these, Krogan's lab has used several viral assays to identify two sets of pharmacological agents that displayed antiviral activity.

COVID-19: The Australian Experience and a Perspective Through a SARS-1 Lens

The NIH COVID-19 Scientific Interest Group is pleased to announce its next lecture, "COVID-19: the Australian Experience and a Perspective Through a SARS-1 Lens," by Kanta Subbarao, M.B.B.S., Director of the WHO Collaborating Centre for Reference and Research on Influenza Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia, June 17. This lecture is now archived.

In a few short months, SARS-CoV-2 has swept through the world infecting more than 7 million people and causing more than 400,000 deaths.  However, the pandemic experience and response in different countries around the world has varied.  The peak of the outbreak has passed in Australia, with more than 7,000 cases and more than 100 deaths, but there is a real  possibility of a second wave of infection. The viruses that caused the SARS outbreak of 2002/2003 and the current COVID-19 pandemic are related betacoronaviruses.  Experience with SARS-1 provides some insights into the COVID-19 pandemic.  In this seminar, Dr. Subbarao will discuss the Australian COVID-19 experience and response and will look back on SARS-1 vaccine development for important lessons that can inform SARS-CoV-2 vaccine design, testing, and implementation.


Toward Understanding COVID-19 Infection, Transmission, and Pathogenesis at Single-Cell Resolution with the Human Cell Atlas


The NIH COVID-19 Scientific Interest Group is pleased to announce its next lecture, "Toward Understanding COVID-19 Infection, Transmission, and Pathogenesis at Single-Cell Resolution with the Human Cell Atlas," by Aviv Regev, Ph.D., Broad Institute, June 3. This lecture is now archived.

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, creates an urgent need for identifying molecular mechanisms that mediate viral entry, propagation, and tissue pathology. Single-cell analysis of healthy- and SARS-CoV-2-infected tissues offers a unique lens to identify these mechanisms. In an international integrated analysis of the Human Cell Atlas Lung Biological Network--which spans more than 100 single-cell and single-nucleus RNA-Seq datasets previously collected from healthy tissues and includes many previously unpublished studies--we identified the cell types throughout the body most likely to be susceptible to viral entry. In line with epidemiological observations, we also identified increased expression of key mediators of SARS-CoV-2 cellular entry associated with increasing age, male gender, and smoking. In addition, we identified a gene program shared by these cells that includes genes that may mediate viral entry and play key immune roles, such as IL6 and its receptor and co-receptor, IL1R; TNF-response pathways; and complement genes. Following these studies, as the pandemic reached our local Boston community, we have adapted existing sample-processing pipelines with our collaborators in Boston hospitals and are using single-cell and spatial genomics techniques to procure, process, and analyze blood and post-mortem tissue from COVID-19 patients. We are using these pipelines to examine the tissue and immune cellular response to COVID-19, particularly to understand the factors underlying its severity in some individuals, and will share our preliminary results.


Structural Studies of Coronavirus Fusion Glycoproteins

The NIH COVID-19 Scientific Interest Group is pleased to announce its next lecture, "Structural Studies of Coronavirus Fusion Glycoproteins," by David Veesler, Ph.D., Assistant Professor of Biochemistry, University of Washington May 27. This lecture is now archived.

SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic. Coronavirus spike (S) glycoprotein trimers promote the virus’s entry into cells and are the main targets of the humoral immune response. We demonstrated that Angiotensin-converting enzyme 2 (ACE2) is a functional entry receptor for this novel coronavirus and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to ACE2, which correlates with the efficient spread of SARS-CoV-2 among humans. We used cryo-electron microscopy to determine the structures of the SARS-CoV-2 S ectodomain trimer, demonstrating spontaneous opening of the receptor-binding domain, and providing a blueprint for the design of vaccines and inhibitors of viral entry. SARS-CoV S murine polyclonal sera potently inhibited SARS-CoV-2 S-mediated entry into target cells, indicating that vaccination can elicit cross-neutralizing antibodies targeting conserved S epitopes. We subsequently isolated a monoclonal antibody (termed S309) from the memory B cells of an individual who recovered from SARS-CoV in 2003 and showed that S309 potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a receptor-binding domain--glycan-containing epitope, which is conserved within the sarbecovirus subgenus--without competing with receptor attachment. Antibody cocktails including S309 further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.


Sailing Close to the Breeze: Hospital Epidemiology in the COVID-19 Pandemic Icon NEW

The NIH COVID-19 Scientific Interest Group is pleased to announce its next lecture, "Sailing Close to the Breeze: Hospital Epidemiology in the COVID-19 Pandemic," by Tara N. Palmore, M.D., Hospital Epidemiologist, NIH Clinical Center, May 20. This lecture is now archived.

For her lecture, Dr. Palmore will discuss infection control related to COVID-19.  Dr. Palmore began her career at the NIH as a staff clinician in the NIAID Laboratory of Clinical Infectious Diseases.  She became deputy hospital epidemiologist in the NIH Clinical Center in 2007 and became hospital epidemiologist in 2014.  As hospital epidemiologist, Dr. Palmore aims to optimize patient safety through prevention of hospital-acquired infections.  Her research interests include modes of nosocomial transmission of multidrug-resistant bacteria, Clostridium difficile and antimicrobial stewardship.

Clinical Trials in Public Health Emergencies: the Ebola and COVID Experiences

The NIH COVID-19 Scientific Interest Group is pleased to announce its next lecture, "Clinical Trials in Public Health Emergencies: the Ebola and COVID Experiences," by Lori Dodd, Ph.D., Mathematical Statistician, Biostatistics Research Branch, NIAID Division of Clinical Research, May 13. This lecture is now archived.

Designing and implementing clinical trials for novel infectious disease treatments brings many challenges, especially during a rapidly evolving pandemic.  A new disease brings uncertainties arising from an imperfect understanding about illness, limited information about proposed countermeasures, and complexities in measuring relevant patient outcomes.  A pandemic adds an overloaded medical system with limited resources for research, heightened pressure to find cures quickly, and unpredictability about potential case numbers.  I will discuss issues related to designing and conducting treatment trials in outbreaks of Ebola and COVID based on my experience with three studies: Prevail II (the West African Ebola virus disease study of ZMapp), PALM (the Democratic Republic of the Congo Ebola virus disease study of ZMapp, mAb114, REGN-EB3 and remdesivir) and ACTT-1 (the multinational, platform COVID-19 study of remdesivir vs placebo.

Animal Models for COVID-19: A Critical Component of the Response to the Pandemic

The NIH COVID-19 Scientific Interest Group is pleased to announce its next lecture, "Animal Models for COVID-19: A Critical Component of the Response to the Pandemic," by Emmie de Wit, Ph.D., chief of the NIAID Molecular Pathogenesis Unit, May 6. This lecture is now archived.

We are learning more about different aspects of COVID-19 disease manifestations on an almost daily basis. Although data on disease in humans are emerging at a steady pace, certain aspects of the pathogenesis of SARS-CoV-2 can only be studied in detail in animal models where repeated sampling and tissue collection is possible. Non-human primate models that recapitulate aspects of human disease are essential for our understanding of the pathogenic processes involved in severe respiratory disease and for the development of medical countermeasures such as vaccines and antivirals. We have developed a rhesus macaque model that recapitulates COVID-19 with regard to virus replication and shedding, the presence of pulmonary infiltrates, histological lesions, and seroconversion. These data allow us to bridge between the rhesus macaques model and the disease observed in humans and to use this animal model to assess the efficacy of medical countermeasures. While a large number of investigational, approved, and repurposed drugs have been suggested for the treatment of COVID-19, preclinical data from animal models can guide a more focused search for effective treatments in humans by ruling out treatments that have no proven efficacy in vivo. Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity, including against coronaviruses, that is currently being investigated in COVID-19 clinical trials worldwide. The therapeutic efficacy of remdesivir was tested in our rhesus macaque model of COVID-19. Remdesivir treatment initiated early during infection had a clear clinical benefit in SARS-CoV-2-infected rhesus macaques.

COVID-19 Diagnostics: The Challenge of Rapid, High-Volume Detection of SARS-CoV-2 Icon NEW

Please join us for "COVID-19 Diagnostics: The Challenge of Rapid, High-Volume Detection of SARS-CoV-2," by Karen Frank, M.D., Ph.D., Chief, Department of Laboratory Medicine, NIH Clinical Center, April 29. This lecture is now archived at

Since the COVID-19 pandemic began, detection of individuals infected with SARS-CoV-2, followed by contact tracing and quarantine, has been critical to slow the spread of disease. After discovery, the coronavirus was sequenced extremely rapidly, and multiple RT-PCR assays were quickly developed and the details shared for use by laboratories worldwide. The molecular assays have excellent performance characteristics with very high sensitivity and specificity. In the United States, the assay designed by the CDC and granted Emergency Use Authorization by the FDA was adopted across the country. In addition, many academic laboratories and commercial manufacturers designed different versions of SARS-CoV-2 tests. The unprecedented need for testing resulted in a severe shortage of all reagents and supplies including collection swabs, transport media, extraction kits, and RT-PCR enzyme mixtures. Creative solutions such as the 3D printing of swabs resulted. A number of studies are underway to determine which specimens (nasopharyngeal, nasal, oropharyngeal, or saliva) are acceptable for testing. Studies that examine viral load from exposure to the end of the disease course are critical for characterizing this sometimes-fatal disease as we work to find treatments. As we develop an algorithm to move out of "stay-at-home lockdown," there is a scramble to develop a high-quality serological assay that would detect neutralizing antibodies.

Rapid COVID-19 Vaccine Development: An Example of the Prototype Pathogen Approach for Pandemic Preparedness

Please join us for "Rapid COVID-19 Vaccine Development: An Example of the Prototype Pathogen Approach for Pandemic Preparedness," by Barney S. Graham, M.D., Ph.D., deputy director of the NIAID Vaccine Research Center, April 22. This lecture is now archived at

The prototype pathogen approach for pandemic preparedness has been applied to the Middle East respiratory syndrome coronavirus (MERS CoV) over the last seven years.  It was informed by structure-based immunogen-design concepts established for respiratory syncytial virus fusion (RSV F) subunit vaccines, and focused on solving coronavirus spike structures, defining mechanisms of CoV neutralization, and evaluating MERS CoV vaccine candidates in collaboration with a commercial mRNA manufacturer.  Prior spike protein engineering experience resulted in rapid sequence selection and using the mRNA manufacturing platform provided rapid Good Manufacturing Practice (GMP) production a COVID-19 mRNA vaccine in record time.  This candidate was tested in mice in approximately 25 days and humans in approximately 65 days from the time the sequence was released.  Clinical and nonclinical evaluation are now proceeding in parallel with hopes to begin efficacy testing before next winter.  The proactive preparation not only facilitated vaccine development but provided a stabilized spike protein reagent that is supporting the development of serological assays.

The Biomedical Research Response to COVID-19: A View from NIAID

Please join us for a special remote lecture, "The Biomedical Research Response to COVID-19: A View from NIAID," by Hilary D.  Marston, M.D., M.P.H., on Wednesday, April 15. This lecture is now archived.

NIAID has a long-standing dual mandate to maintain a robust portfolio of research in its key focus areas and to respond to emerging and re-emerging infectious diseases (EIDs).  With this mandate, NIAID has also sought to improve EID-response preparedness, working in partnership with other U.S.  government research entities, industry, academia, and international public-health organizations.  This preparedness planning helped the institute respond rapidly to COVID-19.  NIAID tapped existing coronavirus expertise and other assets to stand up research programs spanning basic virology and immunology through to countermeasure development (diagnostics, therapeutics, and vaccines).  As the outbreak has expanded, so too has the NIAID research program and the scope of the problems it seeks to solve.  As the COVID-19 pandemic has grown, it has become increasingly clear that the biomedical research response must draw upon the collective expertise of many NIH Institutes and Centers. 


Visit the National Academies Press at

Login or register to get access to free PDF downloads of thousands of scientific reports. Examples:

  • How People Learn, Volumes I and II
  • Attribution of Extreme Weather Events in the Context of Climate Change
  • Barriers and Opportunities for 2-year and 4-year STEM Degrees
  • Science, Evolution, and Creationism

Virtual Keystone Symposia

offers free, on-demand and live-streaming of scientific content, highlighting today's breakthroughs in basic research, translational impacts and global health topics. Videos are available on demand after the live sessions.

Register to hear from global research leaders about new directions in biomedical research and innovation, from cancer immunotherapy to advances in vaccinology, bioinformatics tools and more.

The Malaria Endgame

Date: April 22, 2020
Time: 12:00PM - 01:30PM
You must be registered to participate!

Covering the current state of the field, and future directions and challenges in the fight to eliminate malaria from endemic countries, this ePanel will highlight various aspects of disease prevention, treatment and control, including:

  • current state of vaccine
  • impact of co-infections in Africa
  • genetically modified mosquitos-benefits, risks and community engagement challenges
  • the disconnect between research and malaria control programs

National Academies Forum on Response to COVID-19

Over the next several weeks, the Board on Higher Education of the National Academies of Sciences, Engineering, and Medicine will be hosting a series of conversations to bring together academic, industry, government, and civic leaders across the country to understand the varied facets of what has happened so far, what is currently happening, and what is expected to happen in the weeks and months ahead. Each conversation will focus on a specific topic related to how the 4,000+ colleges and universities—and the researchers who work there—are supporting the response efforts. 

Sessions begin April 9th and are scheduled for 3:00 to 4:30 pm (EDT) and cover topics such as How Can Researchers Help the National Response Efforts? How Can and Are Laboratories Shifting Research Agendas? How Can We Provide Policy Advice to the Nation Faster? Recordings of all sessions are available after the live sessions.

PBS Film: “Ken Burns presents The Gene: An Intimate History” -- aired April 7 & 14. You can now stream it from


A new PBS film, “Ken Burns presents The Gene: An Intimate History,” based on the book by Dr. Siddhartha Mukherjee, will air in two parts: tomorrow, April 7 at 8 pm ET and next Tuesday, April 14 at 8 pm ET.  Dr. Mukherjee shared his insights on the book with NIH staff in April 2017 as part of the NIH Big Read series (

For more than two years, the National Human Genome Research Institute (NHGRI) has been proud to support the education and outreach associated with this film, and the NIH Office of the Director, the National Institute of General Medical Sciences, and others across NIH have also contributed substantially.

The film describes the history of genetics, from Mendel to modern day. It brings to life the story of today’s revolution in medical science through present-day tales of patients and doctors at the forefront of the search for genetic treatments, interwoven with a compelling history of the discoveries that made this possible and the ethical challenges raised by the ability to edit DNA with precision.

The filmmakers interviewed many NIH staff and NIH-funded researchers in making the documentary, and you will see multiple NIH employees featured in the final cut. For example, Dr. Francis Collins and I were given the opportunity to recount the excitement of the Human Genome Project and its incredible legacy, including the birth of NHGRI and the increased investments in genetics and genomics by all parts of NIH.

I hope that you will tune in this Tuesday night to watch the first part of the two-part film. A preview, along with how and where to watch it, is available on the PBS website (

All the best,

Eric Green, MD/Ph
Director, National Human Genome Research Institute   


NIGMS Virtual Learning Resources for Scientists at All Career Stages

To assist with virtual learning during the COVID-19 pandemic, NIGMS has assembled valuable resources to support its trainee and educator communities. These resources apply to all levels, ranging from community college students to faculty.

  • Clearinghouse for Training Modules to Enhance Data Reproducibility
    A variety of free training modules, workshops, and online courses aimed at enhancing rigor and reproducibility in research.
  • iBiology 
    A collection of high-quality, free online videos of scientists talking about their research, career paths, and related topics. Several complete courses are also available in areas including experimental design, microscopy, and image analysis. iBiology also has resources for flipped-classroom teaching.
  • National Research Mentoring Network 
    A free, web-based platform designed to help undergraduates, graduate students, and postdocs connect professionally through online mentoring and networking activities.


Memorial Sloan Kettering Science Spotlight

In this time of a global pandemic, relying on science to help us make decisions is more important than ever. Memorial Sloan Kettering is proud to announce MSK Science Spotlight, a twice-weekly scientific seminar series featuring illuminating lectures by today’s leaders in basic and translational biomedical science. To ensure the widest possible audience, seminars will be viewable via livestream and are open to everyone.

The kickoff speaker in the series, on Monday April 6, 2020 at 4:30 PM, will be Michael S. Glickman, MD, incumbent of the Alfred P. Sloan Chair and Director of the Center for Experimental Immuno-Oncology at MSK, and Member of the Immunology Program in the Sloan Kettering Institute. Dr. Glickman is a physician-scientist who investigates the physiology and pathogenic mechanisms of mycobacteria, including the major human pathogen M. tuberculosis, responsible for the global pandemic of tuberculosis. He is helping to lead MSK’s multifaceted scientific response to the evolving COVID-19 pandemic. The title of Dr. Glickman’s talk is “The Intersection of Cancer and Infection in the Time of COVID.”

You can stream the seminar live at No registration is required.

Additional seminars will take place every Monday and Wednesday at 4:30 PM and will last 60 minutes, including 15 minutes for Q & A. Upcoming seminars in April feature the following speakers:

April 8, 2020, 4:30 PM: Charles L. Sawyers, MD, Investigator, Howard Hughes Medical Institute; Marie-Josée and Henry R. Kravis Chair in Human Oncology and Pathogenesis; Chair, Human Oncology & Pathogenesis Program, MSK

April 13, 2020, 4:30 PM: Scott W. Lowe, PhD, Investigator, Howard Hughes Medical Institute; Chair, Geoffrey Beene Cancer Research Center, MSK; Chair, Cancer Biology & Genetics Program, Sloan Kettering Institute

April 15, 2020, 4:30 PM: To Be Announced

April 20, 2020, 4:30 PM: Dana Pe'er, PhD, Chair, Computational & Systems Biology Program, Sloan Kettering Institute; Scientific Director, Metastasis & Tumor Ecosystems Center, MSK

April 22, 2020, 4:30 PM: Christine Mayr, MD, PhD, Member, Cancer Biology & Genetics Program, Sloan Kettering Institute

April 27, 2020, 4:30 PM: Michel Sadelain, MD, PhD, Stephen and Barbara Friedman Chair; Director, Center for Cell Engineering, MSK; Member, Immunology Program, Sloan Kettering Institute

The Science Spotlight series will be hosted by four MSK faculty: Omar Abdel-Wahab, Danwei Huangfu, Andrea Schietinger, and Tuomas Tammela.

Seminar speakers, dates, and times can be found here. Video recordings of previous seminars will also be available.

MSK Science Spotlight is brought to you by MSK’s Sloan Kettering Institute and its Office of Scientific Education and Training. For more information, contact